Market Place
Sourcing Support
Tenax Therapeutics Reports Q2 2024 Results And Corporate Update
13 Aug 2024 //
GLOBENEWSWIRE
Tenax New Patent for Levosimendan in PH-HFpEF
30 Apr 2024 //
GLOBENEWSWIRE
Tenax Therapeutics Hosts KOL Event
09 Apr 2024 //
GLOBENEWSWIRE
Tenax Provides Business and Development Updates with FY23 Financial Results
28 Mar 2024 //
GLOBENEWSWIRE
Tenax Therapeutics Announces Oral Presentation of Levosimendan
29 Feb 2024 //
PRESS RELEASE
Tenax Announces License Amendment that Expands Rights to Levosimendan
20 Feb 2024 //
GLOBENEWSWIRE
Tenax Therapeutics Enrolls First Patient in Ph 3 LEVEL Study Evaluating TNX-103
07 Feb 2024 //
GLOBENEWSWIRE
Unveiling the Power of Levosimendan: A Breakthrough in Heart Failure Treatment
17 Jan 2024 //
PRESS RELEASE
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103
13 Nov 2023 //
GLOBENEWSWIRE
Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in PH-HFpEF
19 Jul 2023 //
GLOBENEWSWIRE
Tenax Granted Notice of Allowance for Patent Application Covering Use of IV Levosimendan
01 Feb 2023 //
GLOBENEWSWIRE
Positive Data Presented at HFSA Annual Meeting Effects of Oral Levosimendan
10 Oct 2022 //
GLOBENEWSWIRE
Tenax Granted U.S. Patent for Subcutaneous Use of Levosimendan (TNX-102)
12 Jan 2022 //
GLOBENEWSWIRE
Tenax Announces New Publication Highlighting Levosimendan Mechanism of Action
12 Aug 2021 //
BUSINESSWIRE
Tenax Therapeutics Gains North American Rights to Oral Levosimendan
15 Oct 2020 //
BIOSPACE
Tenax Therapeutics Gains North American Rights Oral Levosimendan
15 Oct 2020 //
BUSINESSWIRE
Orion’s phase 3 REFALS trial evaluating the efficacy of oral levosimendan
28 Jul 2020 //
GLOBENEWSWIRE
Tenax Therapeutics Reports Positive Results from Phase 2 Trial of Levosimendan
02 Jun 2020 //
BUSINESSWIRE
Tenax Therapeutics Announces Last Patient Completes Final Visit in its Phase 2
09 Apr 2020 //
BUSIBNESSWIRE
Tenax Therapeutics Provides Update on Phase 2 Pulmonary
13 Jan 2020 //
BUSINESSWIRE
Tenax Therapeutics Provides Update on Ph2 Pulmonary Hypertension Clinical Trial
31 Oct 2019 //
BUSINESSWIRE
Tenax Therapeutics Enrolls First Patient for Ph2 Pulmonary Hypertension CTRL
11 Mar 2019 //
BUSINESSWIRE
Newly discovered ALS mechanism could point the way to novel drugs
06 Sep 2018 //
FIERCE BIOTECH
Orion takes repurposed heart drug into phase 3 for ALS
06 Jul 2018 //
FIERCE BIOTECH
Tenax Announces Design for Levosimendan Ph 2 Trial in PH-HFpEF Pts
01 Jun 2018 //
BUSINESSWIRE
Tenax`s Announces New Scientific Publication of Preclinical Data Levosimendan
01 Mar 2018 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.